Purported Benefits, Side Effects & More


Purported Benefits, Side Effects & More

Common Names

  • Magic mushrooms
  • Shrooms
  • Boomers
  • Buttons
  • Purple passion
  • Mushies (>12 other terms)

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.

What is it?

Psilocybin is a substance found in more than 200 species of fungi commonly known as magic mushrooms.

Psilocybin mushrooms are eaten for their hallucinogenic effects. They are also brewed as teas or added to other foods to mask their bitter taste.

What are the potential uses and benefits?

Psilocybin is used to:

  • Treat tobacco addiction
  • Treat alcohol addiction
  • Treat depression
  • Reduce anxiety (strong feelings of worry or fear)
  • Treat obsessive compulsive disorder
  • Treat migraines
  • Improve mood
  • Improve cognition (the mental action of acquiring knowledge and understanding through thought)

Psilocybin also has other uses that haven’t been studied by doctors to see if they work.

Talk with your healthcare providers before taking psilocybin. It can interact with some medications and affect how they work. For more information, read the “What else do I need to know?” section below.

What are the side effects?
  • Headache that lasts for a short time a day after the treatment
  • Increased blood pressure
  • Increased heart rate
  • Anxiety (strong feelings of worry or fear)
  • Confusion
  • Fatigue (feeling more tired than usual)
  • Nausea (feeling like you’re going to throw up)
  • Vomiting (throwing up)
  • Dizziness
  • Suicidal ideation or behavior (thinking about or planning suicide), or self-injury
What else do I need to know?

Don’t take psilocybin if:

  • You have a history of schizophrenia, psychosis, bipolar disorder, and borderline personality disorder. Psilocybin may make these conditions worse.
  • You have serious or uncontrolled heart conditions. Psilocybin can make these conditions worse.
  • You’re pregnant or breastfeeding. Psilocybin may not be safe for you.
  • You’re taking antidepressant or antipsychotic medications. They can increase the effects of psilocybin.  
  • You’re taking medications that increase serotonin, a chemical made by some nerve cells. These include drugs that lower your appetite and reduce anxiety. When taken with psilocybin, they can increase serotonin in your body. Higher levels of serotonin can cause reactions that include increased heart rate, sweating, seizures and muscle breakdown.

For Healthcare Professionals

Scientific Name
3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate
Clinical Summary

Psilocybin is an indole alkaloid found in more than 200 species of fungi commonly referred to as “magic mushrooms,” many of which belong to the genus Psilocybe. Historically used for religious ceremonies and healing rituals by Mesoamerican cultures, psilocybin mushrooms are ingested orally for their hallucinogenic effects. They are also brewed as teas or added to other foods to mask their bitter taste. Upon consumption, psilocybin is converted to psilocin, which has psychoactive properties.

Psilocybin is a Schedule I substance under the Controlled Substances Act, but renewed interest in its therapeutic potential for treating mental health issues has led to a surge in clinical research in recent years. Randomized controlled trials have reported benefits of psilocybin-assisted therapy for

Systematic reviews/meta-analyses showed

  • Improvements in end-of-life anxiety (9)
  • Positive effects on existential and spiritual well-being, quality of life and acceptance in patients with terminal illness (10)
  • Effectiveness comparable to escitalopram for long-standing depression (11)

Preliminary findings also suggest beneficial effects in individuals with

  • Obsessive compulsive disorder (OCD) (12)
  • Cluster headaches (13) (14) (49)
  • Migraines (15)
  • Demoralization with an AIDS diagnosis (16)

In cancer patients with psychological distress, psilocybin affected

  • Reductions in suicidal ideation (17)
  • Rapid, significant, and sustained reductions in depression and anxiety (18) (19) (20)
    Notably, mystical experience – characterized by deep feelings of meaning/sacredness, interconnectedness, transcendence of time and space, and a strong positive mood – was positively correlated with reductions in depression (18).
  • Integrated group and individual psilocybin-assisted therapy may improve patients’ experience (50).

Microdosing: Consuming very low doses of psychedelics for improving mood, concentration, creativity, and cognitive function is also gaining popularity. Studies are mixed on whether microdosing can improve mood and mental health (21) (22) (23) (24). A case series suggests it may relieve chronic neuropathic pain (25).

Legal Status: Under federal law, the use, sale and possession of psilocybin is illegal. Given the promising preliminary data, the USFDA granted “breakthrough therapy” status to psilocybin in 2018 for treatment-resistant depression, and in 2019 for major depressive disorder. This designation can help minimize the burden of federal regulations that impede research and drug development. Many states are also moving toward decriminalizing psilocybin for therapeutic or recreational purposes: Oregon became the first to both decriminalize and legalize psilocybin for therapeutic use, with ballot initiatives underway in Colorado and California (26).

The American Psychiatric Association supports research into psychedelics, but states that “clinical treatments should be determined by scientific evidence in accordance with applicable regulatory standards and not by ballot initiatives or popular opinion” (46).

In Summary, emerging evidence suggests that psilocybin improves mental health outcomes in patients with multiple psychiatric conditions. With increasing public interest and acceptance of psychedelic therapies, larger trials with more diverse populations, standardized dosages, stronger blinding/controls, research on long-term effects, as well as clear regulations and guidelines are needed to inform future clinical practice (27).

It is important to note that although psilocybin has low potential of addiction (28) and is associated with lower risk of adverse effects compared to other psychoactive drugs such as LSD or MDMA, it can cause acute psychological distress, dangerous behavior and sustained psychological discomfort in uncontrolled environments (29). Individuals who abuse psilocybin mushrooms may also risk poisoning because their morphological similarities to some poisonous mushrooms could lead to misidentification.

Purported Uses and Benefits
  • Tobacco use disorder
  • Alcohol use disorder
  • Depression
  • Anxiety
  • Obsessive compulsive disorder
  • Migraines
  • Mood
  • Cognition
Mechanism of Action

Psilocin, the active metabolite of psilocybin, is known to produce perceptual changes, altering one’s awareness of surroundings, thoughts, and feelings. These effects are exerted primarily via serotonin (5-hydroxytryptamine) type 2A receptor agonism (30). This functional selectivity to the 5-HT2A receptor leads to releasing increased levels of glutamate, which may also contribute to the psychedelic effects. The visual hallucinations associated with psilocin are likely due to overexpression of 5-HT2A receptors in the visual cortex (31).

Additionally, psilocybin is thought to decrease negative affect and the neural correlates of negative affect, thought to be one of the mechanisms underlying its effects against a variety of mental disorders (32).

Following oral consumption, the bioavailability of psilocin was reported to be approximately 50%, with detectable levels in the plasma after 30 min (33). Recent studies using a 25 mg dose of psilocybin found the onset of action at 20-40 minutes with effects peaking at 60-90 minutes, and active duration between 4-6 hours (34). The Tmax (maximal plasma concentration) was 18.7 ng/ml - 20 ng/ml at 120 minutes (35) (36). Nearly 80% of the circulating psilocin is metabolized by hepatic phase II glucuronidation (conjugation) through UGT 1A10 and UGT 1A9 enzymes. Psilocin is completely excreted within 24 h with much of it occurring within the first 8 h (33) (37).

  • Those with a personal or family history of schizophrenia, psychosis, bipolar disorder, and borderline personality disorder should avoid psilocybin (18) (6) (3) (4) (5).
  • Those with serious or uncontrolled cardiovascular conditions should avoid psilocybin (6).
  • Pregnant and breastfeeding women should also avoid it given the insufficient evidence to assess risks.
Adverse Reactions

Clinical studies have reported transient headache the day following the treatment, increase in blood pressure and heart rate, anxiety, confusion, fatigue, nausea, vomiting, dizziness and suicidal ideation or behavior or self-injury. (3) (20) (5) (8) (2) (12) (6) (28) (38) (51)

Case Reports: Psilocybin use has also been associated with Takotsubo cardiomyopathy (39), rhabdomyolysis (40), prolonged mania, psychosis and severe depression (41), unpredictable behavior (42), toxic metabolic encephalopathy (52), manic episodes (43) (53), seizures (54), cardiac arrest (55) and persistent pupillary changes (44).

Herb-Drug Interactions
  • Antidepressants/Antipsychotics: Concurrent use may result in heightened or blunted psychedelic experience (33).
  • Serotonergic drugs: Simultaneous use may cause serotonin syndrome in which excessive serotonin signaling may potentially lead to life-threatening adverse reaction (28).
  • UGT substrates: Psilocin is metabolized by UGT 1A10 and 1A, and therefore, concurrent use of medications that inhibit or induce UGT enzymes should be avoided (37) (45).
Dosage (OneMSK Only)
  1. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. Jan 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135
  2. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. Mar 2015;29(3):289-99. doi:10.1177/0269881114565144
  3. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. Jul 2016;3(7):619-27. doi:10.1016/s2215-0366(16)30065-7
  4. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). Feb 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x
  5. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. Apr 15 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994
  6. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. May 1 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285
  7. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. Feb 2022;36(2):151-158. doi:10.1177/02698811211073759
  8. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. Nov 3 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443
  9. Yu CL, Yang FC, Yang SN, et al. Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. Psychiatry Investig. Oct 2021;18(10):958-967. doi:10.30773/pi.2021.0209
  10. Schimmel N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology (Berl). Jan 2022;239(1):15-33. doi:10.1007/s00213-021-06027-y
  11. Kisely S, Connor M, Somogyi AA, Siskind D. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Aust N Z J Psychiatry. Mar 2023;57(3):362-378. doi:10.1177/00048674221083868
  12. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. Nov 2006;67(11):1735-40. doi:10.4088/jcp.v67n1110
  13. Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. J Psychoactive Drugs. Nov-Dec 2015;47(5):372-81. doi:10.1080/02791072.2015.1107664
  14. Sewell RA, Halpern JH, Pope HG, Jr. Response of cluster headache to psilocybin and LSD. Neurology. Jun 27 2006;66(12):1920-2. doi:10.1212/01.wnl.0000219761.05466.43
  15. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics. Jan 2021;18(1):534-543. doi:10.1007/s13311-020-00962-y
  16. Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. Oct 2020;27:100538. doi:10.1016/j.eclinm.2020.100538
  17. Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. Apr 9 2021;4(2):553-562. doi:10.1021/acsptsci.1c00020
  18. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. Dec 2016;30(12):1181-1197. doi:10.1177/0269881116675513
  19. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. Jan 2011;68(1):71-8. doi:10.1001/archgenpsychiatry.2010.116
  20. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. Dec 2016;30(12):1165-1180. doi:10.1177/0269881116675512
  21. Ryan RS, Copello A, Fox AP. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. BMC Psychiatry. Mar 14 2023;23(1):160. doi:10.1186/s12888-023-04628-9
  22. Rootman JM, Kiraga M, Kryskow P, et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Sci Rep. Jun 30 2022;12(1):11091. doi:10.1038/s41598-022-14512-3
  23. Hutten N, Mason NL, Dolder PC, Kuypers KPC. Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Front Psychiatry. 2019;10:672. doi:10.3389/fpsyt.2019.00672
  24. Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. Aug 2 2022;12(1):307. doi:10.1038/s41398-022-02039-0
  25. Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: a case series. Pain. Apr 1 2023;164(4):698-702. doi:10.1097/j.pain.0000000000002778
  26. Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug Legislative Reform and Legalization in the US. JAMA Psychiatry. Jan 1 2023;80(1):77-83. doi:10.1001/jamapsychiatry.2022.4101
  27. Bender D, Hellerstein DJ. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology (Berl). Jun 2022;239(6):1907-1932. doi:10.1007/s00213-021-06049-6
  28. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. Aug 2008;22(6):603-20. doi:10.1177/0269881108093587
  29. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. Dec 2016;30(12):1268-1278. doi:10.1177/0269881116662634
  30. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. May 2019;197:83-102. doi:10.1016/j.pharmthera.2018.11.010
  31. Ling S, Ceban F, Lui LMW, et al. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. Jan 2022;36(1):17-30. doi:10.1007/s40263-021-00877-y
  32. Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. Feb 10 2020;10(1):2214. doi:10.1038/s41598-020-59282-y
  33. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. Oct 2002;7(4):357-64. doi:10.1080/1355621021000005937
  34. Tylš F, Páleníček T, Horáček J. Psilocybin—summary of knowledge and new perspectives. Eur Neuropsychopharmacol. Mar 2014;24(3):342-56. doi:10.1016/j.euroneuro.2013.12.006
  35. Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. Apr 2022;111(4):886-895. doi:10.1002/cpt.2487
  36. Dahmane E, Hutson PR, Gobburu JVS. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. Clin Pharmacol Drug Dev. Jan 2021;10(1):78-85. doi:10.1002/cpdd.796
  37. Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. Feb 2017;49(1):84-91. doi:10.1080/03602532.2016.1278228
  38. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). Dec 2011;218(4):649-65. doi:10.1007/s00213-011-2358-5
  39. Kotts WJ, Gamble DT, Dawson DK, Connor D. Psilocybin-induced takotsubo cardiomyopathy. BMJ Case Rep. May 17 2022;15(5)doi:10.1136/bcr-2021-245863
  40. Suleiman M, Basu A, Belal S, Jacob T. From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder. J Nerv Ment Dis. Aug 1 2022;210(8):638-639. doi:10.1097/nmd.0000000000001489
  41. Barber G, Nemeroff CB, Siegel S. A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. Am J Psychiatry. Dec 1 2022;179(12):892-896. doi:10.1176/appi.ajp.22010073
  42. Honyiglo E, Franchi A, Cartiser N, et al. Unpredictable Behavior Under the Influence of “Magic Mushrooms”: A Case Report and Review of the Literature. J Forensic Sci. Jul 2019;64(4):1266-1270. doi:10.1111/1556-4029.13982
  43. Hendin HM, Penn AD. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report. Bipolar Disord. Nov 2021;23(7):733-735. doi:10.1111/bdi.13095
  44. Al-Imam A. Could Hallucinogens Induce Permanent Pupillary Changes in (Ab)users? A Case Report from New Zealand. Case Rep Neurol Med. 2017;2017:2503762. doi:10.1155/2017/2503762
  45. MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217. doi:10.3389/fpsyt.2022.1040217
  46. Alpert JE, McDonald WM, Nemeroff CB, Rodriquez C. Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions. APA Official Actions. July 2022. Accessed April 14, 2023.
  47. Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023 Sep;48(10):1492-1499.
  48. Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.  JAMA. 2023 Sep 5;330(9):843-853.
  49. Schindler EAD, Sewell RA, Gottschalk CH, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial.  J Neurol Sci. 2024 Apr 2;460:122993.
  50. Beaussant Y, Tarbi E, Nigam K, et al. Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.  Cancer. 2024 Apr 1;130(7):1147-1157.
  51. Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Apr 1;7(4):e245960.
  52. Ho C, Crawford JR. Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent.  BMJ Case Rep. 2024 Mar 5;17(3):e259721.
  53. Halim HJ, Burk BG, Fargason RE, Birur B. Manic episode following psilocybin use in a man with bipolar II disorder: a case report.  Front Psychiatry. 2023 Sep 22;14:1221131.
  54. Blond BN, Schindler EAD. Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Front Neurol. 2023 Jun 29;14:1214969. 
  55. Bae S, Vaysblat M, Bae E, Dejanovic I, Pierce M. Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis.  Cureus. 2023 May 7;15(5):e38669. 
Email your questions and comments to [email protected].

Last Updated